Articles with public access mandates - Matthijs Versteegh, PhDLearn more
Not available anywhere: 2
Are health state valuations from the general public biased? A test of health state reference dependency using self‐assessed health and an efficient discrete choice experiment
MF Jonker, AE Attema, B Donkers, EA Stolk, MM Versteegh
Health economics 26 (12), 1534-1547, 2017
Mandates: Netherlands Organisation for Scientific Research
Can time heal all wounds?
A de Hond, P Bakx, M Versteegh
Mandates: US National Institutes of Health, Federal Ministry of Education and Research …
Available somewhere: 34
Dutch tariff for the five-level version of EQ-5D
MM Versteegh, KM Vermeulen, SMAA Evers, GA De Wit, R Prenger, ...
Value in health 19 (4), 343-352, 2016
Mandates: Netherlands Organisation for Health Research and Development
When is it too expensive? Cost-effectiveness thresholds and health care decision-making
W Brouwer, P van Baal, J van Exel, M Versteegh
The European Journal of Health Economics 20, 175-180, 2019
Mandates: Netherlands Organisation for Health Research and Development
Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma
S de Groot, WK Redekop, MM Versteegh, S Sleijfer, E Oosterwijk, ...
Quality of Life Research 27, 115-124, 2018
Mandates: Netherlands Organisation for Health Research and Development
Guidance for the harmonisation and improvement of economic evaluations of personalised medicine
H Vellekoop, S Huygens, M Versteegh, L Szilberhorn, T Zelei, B Nagy, ...
Pharmacoeconomics 39 (7), 771-788, 2021
Mandates: European Commission
Comparing the effectiveness and cost-effectiveness of self-management interventions in four high-priority chronic conditions in Europe (COMPAR-EU): a research protocol
M Ballester, C Orrego, M Heijmans, P Alonso-Coello, MM Versteegh, ...
BMJ open 10 (1), e034680, 2020
Mandates: European Commission
Financing and reimbursement models for personalised medicine: a systematic review to identify current models and future options
R Koleva-Kolarova, J Buchanan, H Vellekoop, S Huygens, M Versteegh, ...
Applied Health Economics and Health Policy 20 (4), 501-524, 2022
Mandates: European Commission
A randomised comparison of the effect of haemodynamic monitoring with CardioMEMS in addition to standard care on quality of life and hospitalisations in patients with chronic …
JJ Brugts, JF Veenis, SP Radhoe, GCM Linssen, M van Gent, ...
Netherlands heart journal 28, 16-26, 2020
Mandates: National Institute for Health Research, UK, Netherlands Organisation for …
Time to tweak the TTO: results from a comparison of alternative specifications of the TTO
MM Versteegh, AE Attema, M Oppe, NJ Devlin, EA Stolk
The European Journal of Health Economics 14, 43-51, 2013
Mandates: Netherlands Organisation for Health Research and Development
The net benefit of personalized medicine: a systematic literature review and regression analysis
H Vellekoop, M Versteegh, S Huygens, IC Ramos, L Szilberhorn, T Zelei, ...
Value in Health 25 (8), 1428-1438, 2022
Mandates: European Commission
Can time heal all wounds? An empirical assessment of adaptation to functional limitations in an older population
A de Hond, P Bakx, M Versteegh
Social Science & Medicine 222, 180-187, 2019
Mandates: US National Institutes of Health, Federal Ministry of Education and Research …
Estimating informal caregiving time from patient EQ-5D data: the Informal CARE Effect (iCARE) Tool
M Gheorghe, RJ Hoefman, MM Versteegh, J van Exel
Pharmacoeconomics 37, 93-103, 2019
Mandates: Netherlands Organisation for Health Research and Development
Would you rather be ill now, or later?
AE Attema, MM Versteegh
Health Economics 22 (12), 1496-1506, 2013
Mandates: Netherlands Organisation for Health Research and Development
Cost-effectiveness analysis of treating patients with NTRK-positive cancer with the histology-independent therapy entrectinib
S Huygens, H Vellekoop, M Versteegh, I Santi, L Szilberhorn, T Zelei, ...
Value in Health 26 (2), 193-203, 2023
Mandates: European Commission
Future medical and non-medical costs and their impact on the cost-effectiveness of life-prolonging interventions: a comparison of five European countries
H Mokri, I Kvamme, L de Vries, M Versteegh, P van Baal
The European Journal of Health Economics 24 (5), 701-715, 2023
Mandates: European Commission
Evaluating the effectiveness and cost-effectiveness of seizure dogs in persons with medically refractory epilepsy in the netherlands: Study protocol for a stepped wedge …
V Wester, S De Groot, T Kanters, L Wagner, J Ardesch, I Corro Ramos, ...
Frontiers in Neurology 11, 3, 2020
Mandates: Netherlands Organisation for Health Research and Development
Burden of illness in people with medically refractory epilepsy who suffer from daily to weekly seizures: 12-month follow-up of participants in the EPISODE study
V van Hezik-Wester, S de Groot, T Kanters, M Versteegh, L Wagner, ...
Frontiers in Neurology 13, 1012486, 2022
Mandates: Netherlands Organisation for Health Research and Development
105P prognostic value of the NTRK fusion biomarker in The Netherlands
I Santi, H Vellekoop, S Huygens, M Rutten-van Molken, M Versteegh
Annals of Oncology 32, S401-S402, 2021
Mandates: European Commission
Performance of the EQ-5D-5L plus respiratory bolt-on in the Birmingham chronic obstructive pulmonary disease cohort study
M Hoogendoorn, S Jowett, AP Dickens, R Jordan, A Enocson, P Adab, ...
Value in Health 24 (11), 1667-1675, 2021
Mandates: National Institute for Health Research, UK
Publication and funding information is determined automatically by a computer program